Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 140

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 140
---
 effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our ordinary shares.” We are subject to changing law and regulations regarding regulatory matters, corporate governance, and public disclosure that have increased our costs and the risk of non -compliance . We are subject to rules and regulations by various governing bodies, including, for example, the SEC, which are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in increased general and administrative expenses and a diversion of management time and attention. Moreover, because these laws, regulations, and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalties (monetary or otherwise) and our business may be harmed. Our ability to achieve or sustain profitability depends on our collection of payment for the tests and services we provide, which we may not be able to do successfully or in a timely manner. We have historically focused primarily on providing our Heritas Diagnostics services to diagnostic laboratories, which provide our tests to hospitals, medical institutions and other laboratories. Since Rewell was launched, we also provide genetic and microbiome tests as direct -to -customerto the general population. Healthcare policy changes that influence the way healthcare is financed or other changes in the market that impact payment rates by institutional or non -institutionalcustomers could also affect our collection rates. If we are unable to convince our distributors and overall consumers of the value and benefit provided by our services, these customers may slow, or stop altogether, their purchases of our tests. We currently do not offer reimbursement to patients in connection with our tests. As such, if in the future third -partypayors do not provide coverage and adequate reimbursement for our tests and testing services, our potential for growth and our ability to collect revenue for these tests and testing services would be limited. 46 Even if payers eventually agree to cover our tests, our billing and collections process may be complicated by the following and other factors, which may be beyond our control: •disputes among payers as to which payer is responsible for payment; •